您的位置:PharmaNews 研发动态 列表
下级分类
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

首页 研发动态 第527页
   下级栏目:药讯快递  新药介绍  不良反应  药物研发  药物临床  

FDA Approves Drug for Chronic Drooling in Children

发布时间:2010-08-02  -  点击:7次  -  字数:1572字
ROCKVILLE, Md., July 28, 2010--The U.S. Food and Drug Administration today approved Cuvposa (glycopyrrolate) Oral Solution to treat chronic severe drooling caused by neurologic disorders in children ages 3 years to 16 years. Drooling...

Abbott's Simcor ( niacin extended-release / simvastatin ) Receives FDA Approval for New Dosage Strengths

发布时间:2010-08-02  -  点击:66次  -  字数:1940字
ABBOTT PARK, Ill., July 28 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR , a cholesterol medication. The new SIMCOR...

Quintiles Announces New European Headquarters

发布时间:2010-08-02  -  点击:9次  -  字数:2103字
Unified, State of the Art Facility Allows Greater Collaboration to Serve Biopharmaceutical Clients RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul 29, 2010 - Quintiles, the only fully integrated biopharmaceutical...

Covance Reports Second Quarter Revenue of $475M and EPS of $0.49; Updates Full-Year Financial Targets

发布时间:2010-08-02  -  点击:59次  -  字数:23214字
PRINCETON, N.J., July 28 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) today reported earnings per diluted share for its second quarter ended June 30, 2010 of 0.49, including 0.09 of facility rationalization and other cost reduction ...

Commonwealth Biotechnologies, Inc. Provides Market Update

发布时间:2010-08-02  -  点击:15次  -  字数:2401字
RICHMOND, Va.--(BUSINESS WIRE)--Jul 28, 2010 - Commonwealth Biotechnologies, Inc. ( CBI ) (CBTE.OB) is providing this update to inform the market regarding its near term plans to move the company into a more viable long term position...

Plant Compound Resveratrol Shown to Suppress Inflammation, Free Radicals, in Humans

发布时间:2010-08-02  -  点击:62次  -  字数:2485字
BUFFALO, N.Y. July 29, 2010-- Resveratrol, a popular plant extract shown to prolong life in yeast and lower animals due to its anti-inflammatory and antioxidant properties, appears also to suppress inflammation in humans, based...

New pathway to Parkinson's and Alzheimer's diseases

发布时间:2010-08-02  -  点击:16次  -  字数:2834字
Sanford-Burnham researchers uncover new clues about the cause of brain cell death in neurodegenerative disorders such as Parkinson's, Alzheimer's and Huntington's diseases LA JOLLA, Calif., July 29, 2010 Although their genetic...

deCODE Shows how Genetic Risk of Kidney Disease Frames Response to Environmental Risk Over Time

发布时间:2010-08-02  -  点击:35次  -  字数:2151字
A SNP on Chromosome 16 Appears to Confer Risk by Affecting how the Renal System Adapts to the Impact of Aging and the Onset of Other Common Diseases REYKJAVIK, Iceland, July 29, 2010/PRNewswire-FirstCall/ -- Scientists at deCODE genetics...

Bionovo to Advance Menerba to Phase 3 Clinical Testing in Europe

发布时间:2010-08-02  -  点击:79次  -  字数:2117字
EMERYVILLE, Calif., July 29 /PRNewswire-FirstCall/ -- Bionovo, Inc. (NASDAQ:BNVI) announced today that it has received final guidance from the European Medicines Agency (EMA) in order to advance Menerba, the company's lead drug candidate...

Geron to Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based Therapy

发布时间:2010-08-02  -  点击:20次  -  字数:4028字
Geron to Study GRNOPC1 in Patients with Acute Spinal Cord Injury MENLO PARK, Calif.--(BUSINESS WIRE)--Jul 30, 2010 - Geron Corporation (Nasdaq:GERN) announced today that the U.S. Food and Drug Administration (FDA) has...

Orexigen Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet

发布时间:2010-08-02  -  点击:22次  -  字数:5152字
- 62% of the Patients Completing Trial on Contrave32 Lost at Least 5% of Body Weight Compared to 23% of Patients on Placebo - Patients Taking Contrave Also Showed Significant Improvement in Markers of Cardiometabolic Risk and...

Basilea Pharmaceutica AG (CH) - Data on Basilea's Toctino in Daily Medical Practice in Germany Presented at Dermatology Congress

发布时间:2010-08-02  -  点击:70次  -  字数:3575字
Basel, Switzerland, July 30, 2010 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today that first results from the TOCCATA observational study were presented at the 22nd Fortbildungswoche f r praktische Dermatologie und Venerologie in...

Study Results Show That Oral Contraceptives/Hormone Replacement Therapy May Protect Against Brain Aneurysms

发布时间:2010-08-02  -  点击:12次  -  字数:3260字
Findings Announced at the Society of NeuroInterventional Surgery (SNIS) 7th Annual Meeting CARLSBAD, Calif., July 30 /PRNewswire-USNewswire/ -- Results from a retrospective, case-control study presented today at the Society...

[不良反应FDA发布奥利司他或致肝损伤的安全性信息

发布时间:2010-07-23  -  点击:26次  -  字数:616字
近日,美国食品药品管理局(FDA)向消费者及医护人员发布消息称:少数服用减肥药奥利司他(orlistat,赛尼可,Xenical/Alli)的患者出现严重肝损伤。 奥利司他由瑞士罗氏公司研制,胶囊剂于1998年在新西兰首次上市,1999年10月在美国上市,规格为120 mg...

[不良反应美国FDA公布新一季安全问题药品清单 礼来抗凝药普拉格雷榜上有名

发布时间:2010-07-23  -  点击:48次  -  字数:440字
2010年6月30日,美国FDA公布了新一季将进行安全问题早期调查的药品清单,该清单反映的是从2010年1月~3月发现的药品安全问题。清单中不乏制药巨头们重推的新产品。 礼来公司2009年新上市的抗凝药普拉格雷(prasugrel,Effient)榜上有名...